Short Interest in OS Therapies Incorporated (NYSEAMERICAN:OSTX) Drops By 16.7%

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 1,293,690 shares, a drop of 16.7% from the February 26th total of 1,552,122 shares. Based on an average daily volume of 676,545 shares, the short-interest ratio is currently 1.9 days. Currently, 4.1% of the company’s shares are short sold.

OS Therapies Price Performance

Shares of OSTX stock traded up $0.08 during trading on Tuesday, reaching $1.41. The company’s stock had a trading volume of 532,604 shares, compared to its average volume of 575,458. OS Therapies has a 1-year low of $1.12 and a 1-year high of $2.57. The stock’s 50-day moving average price is $1.40 and its 200 day moving average price is $1.66. The company has a market capitalization of $49.65 million, a price-to-earnings ratio of -1.72 and a beta of -3.80.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.41) EPS for the quarter. On average, sell-side analysts anticipate that OS Therapies will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On OS Therapies

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of OS Therapies during the second quarter worth about $63,000. Bridgeway Capital Management LLC purchased a new stake in shares of OS Therapies in the 2nd quarter valued at approximately $47,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies in the 3rd quarter valued at $40,000. CM Management LLC raised its holdings in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of OS Therapies during the 3rd quarter worth $169,000.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Friday. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.50.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.